iNDICA NEWS BUREAU-
Sana Biotechnology, Inc., a company that creates and delivers engineered cells as medicines for patients, announced the appointment of an accomplished Indian-origin drug developer as Executive Vice President and chief scientific officer.
“We are thrilled to welcome Dhaval Patel, M.D., Ph.D., to Sana’s senior leadership team and look forward to partnering with him to build the company, maximize the value of our current pipeline, and secure our long-term future,” said Steve Harr, Sana’s President and Chief Executive Officer. “Through decades of experience in research, drug discovery, drug development, and clinical care, Dhaval has successfully led research and early development programs with substantial contributions to the advancement of 10 FDA-approved treatments. His expertise in immunology and autoimmune diseases make him ideally suited to help advance our clinical pipeline, particularly for B-cell mediated autoimmune diseases and type 1 diabetes, and accelerate our innovation.”
Sana Biotechnology, Inc. is focused on creating and delivering engineered cells as medicines for patients. The company treats patients by repairing and controlling genes, replacing missing or damaged cells, and making its therapies available to patients. Sana has operations in Seattle, WA, Cambridge, MA, South San Francisco, CA, Bothell, WA and Rochester, NY.
Dr. Patel was previously Executive Vice President and Chief Scientific Officer at UCB, where he played a key role in its recent pipeline transformation. He and his teams contributed to the registration of bimekizumab (Bimzelx®), rozanolixizumab (Rystiggo®), and zilucoplan (Zilbrysq®). Before UCB, Dr. Patel spent 10 years at Novartis, most recently as the Head of Research at the Novartis Institutes for BioMedical Research (NIBR) Europe.
During his tenure, he led research in autoimmune, transplantation, and inflammation disease areas contributing to the registration of secukinumab (Cosentyx®), fingolimod (Gilenya®), siponimod (Mayzent®), canakinumab (Ilaris®), everolimus (Zortress®/Certican®, Afinitor®), leniolisib (Joenja®), and iptacopan (Fabhalta®) in multiple indications.
He was also an Entrepreneur in Residence at the Novartis Venture Fund. Prior to joining industry, Dr. Patel was an Eminent Professor of Medicine, Chief of Rheumatology, Allergy and Clinical Immunology, and Director of the Thurston Arthritis Research Center at the University of North Carolina in Chapel Hill. He also spent nine years at the Duke University School of Medicine, culminating in his position as the Chief of the Division of Allergy and Immunology. Dr. Patel received his B.S., M.D., and Ph.D. in Microbiology and Immunology from Duke University, and is board-certified in internal medicine, rheumatology, and allergy & immunology.
“I am delighted to join Sana at this exciting time of growth. Our hyperimmune platform provides a unique opportunity to push the boundaries of science and transform the future for patients. With four ongoing clinical trials across seven indications, including in B-cell mediated autoimmune diseases, type 1 diabetes, and blood cancers, we are poised to take a significant step forward in the company’s mission to bring innovative, life-changing therapies to patients in need. I am eager to collaborate with this talented team to accelerate our journey towards groundbreaking advancements and real-world impact,” Dr. Patel added.